NCT06393374
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 83 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 49 words
- Trial sites expanded: 314 → 317 locations
- Secondary endpoints: details revised at 7 of 8 entries
- Minor Site details revised at 3 of 314 sites
- Minor Trial sites expanded: 311 → 314 locations
- Minor Site details revised at 1 of 311 sites
- Notable Eligibility criteria expanded, about 36 words
- Study sites: 310 to 311
- Secondary endpoints: details revised at 4 of 8 entries
Show 9 earlier versionsHide 9 earlier versions
- Minor Study sites revised (310)v77
- Minor Study sites: 309 to 310v76
- Minor Study sites: 308 to 309v75
- Minor Site details revised at 1 of 308 sitesv74
- Minor Study sites: 307 to 308v73
- Minor Study sites: 306 to 307v72
- Minor Study sites: 305 to 306v71
- Minor Study sites: 304 to 305v70
- Minor Study sites: 303 to 304v69
- Minor Trial sites expanded: 299 → 303 locationsv68
- Minor Study sites: 297 to 299v67
- Minor Trial sites expanded: 293 → 297 locationsv66
- Minor Study sites: 292 to 293v65
- Minor Trial sites expanded: 288 → 292 locationsv64
- Minor Study sites: 287 to 288v63
- Minor Study sites: 286 to 287v62
- Minor Study sites: 285 to 286v61
- Minor Study sites: 284 to 285v60
- Minor Study sites: 281 to 284v59
- Minor Study sites: 280 to 281v58
- Minor Study sites: 279 to 280v57
- Minor Site details revised at 2 of 279 sitesv56
- Minor Study sites: 276 to 279v55
- Minor Study sites: 275 to 276v54
- Minor Study sites: 272 to 275v53
- Minor Study sites: 271 to 272v52
- Minor Study sites: 270 to 271v51
- Minor Study sites: 266 to 270v50
- Minor Study sites revised (266)v49
- Minor Study sites: 263 to 266v48
- Minor Study sites: 262 to 263v47
- Minor Study sites revised (262)v46
- Minor Study sites: 258 to 262v45
- Minor Study sites: 255 to 258v44
- Minor Study sites: 252 to 255v43
- Minor Study sites: 251 to 252v42
- Minor Study sites: 248 to 251v41
- Minor Study sites: 245 to 248v40
- Minor Study sites: 242 to 245v39
- Minor Site details revised at 2 of 242 sitesv38
- Minor Study sites: 240 to 242v37
- Minor Site contacts updated at 2 of 240 sitesv36
- Minor Study sites: 236 to 240v35
- Minor Site contacts updated at 1 of 236 sitesv34
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Participants receive pembrolizumab every 6 weeks (q6w) in combination with sacituzumab tirumotecan every 2 weeks (q2w) for 24 weeks. In addition, participants receive an antihistamine, an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to sacituzumab tirumotecan infusions.
Participants receive pembrolizumab q6w or pembrolizumab q6w in combination with capecitabine (twice daily \[BID\] on Days 1 to 14 and 22 to 35 every 42 days x 4 \[2 weeks 1, 1 week off\]) for 24 weeks.
Biologicals: Pembrolizumab, Sacituzumab tirumotecan
Drugs: Capecitabine
Sites
317 sites in 31 countries
United States 94, Japan 26, Germany 19, Canada 18, France 18, Italy 14, Spain 10, Poland 9, Brazil 8, Argentina 7, United Kingdom 7, Czechia 6, Denmark 6, Greece 6, Israel 6, Mexico 6, Sweden 6, Austria 5, South Korea 5, Switzerland 5, Turkey (Türkiye) 5, Australia 4, Colombia 4, Finland 4, Portugal 4, Belgium 3, Hong Kong 3, Ireland 3, Norway 3, Malaysia 2, Singapore 1